Pancreatic Cancer Research

ResearcherGerman Cancer Research CenterActive in the last 2 years

Jan Goesta D’Haese

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0002-7827-8753; OpenAlex author ID A5055212637. Sources: OpenAlex.

Their work

Papers
31 (first author 3, last author 6)
Trials
0
Grants
0
Labs led
1
Collaborators
112
Papers, trials and grants by year

2014: 1 paper · 2015: 1 paper · 2016: 2 papers · 2017: 1 paper · 2018: 3 papers · 2019: 6 papers · 2020: 8 papers · 2021: 3 papers · 2022: none · 2023: 2 papers · 2024: none · 2025: 3 papers · 2026: 1 paper

Papers 31

  1. The Vitamin D3 Analog Calcipotriol Attenuates Pancreatic Cancer Malignancy via Downregulating Thrombospondin 1 in Pancreatic Stellate Cells. Co-author DOI 10.1155/mi/2632235↗
  2. Prognostic value of tumor-infiltrating lymphocytes, tumor associated neutrophils and metabolic checkpoint molecules on survival of patients with metastatic pan… Co-author DOI 10.1016/j.sipas.2025.100320↗
  3. Microbiome Dysbiosis With Enterococcus Presence in the Upper Gastrointestinal Tract Is a Risk Factor for Mortality in Patients Undergoing Surgery for Pancreati… Co-author DOI 10.1097/sla.0000000000006210↗
  4. Perioperative outcomes in an age-adapted analysis of the German StuDoQ|Pancreas registry for PDAC. Co-author DOI 10.1186/s12893-024-02647-1↗
  5. SPOCK2 gene expression is downregulated in pancreatic ductal adenocarcinoma cells and correlates with prognosis of patients with pancreatic cancer. Co-author DOI 10.1007/s00432-023-04845-5↗
  6. Precision Oncology in Pancreatic Cancer: Experiences and Challenges of the CCCMunich LMU Molecular Tumor Board. Co-author DOI 10.1007/s11523-023-00950-0↗
  7. Influence of Klebsiella pneumoniae and quinolone treatment on prognosis in patients with pancreatic cancer. Co-author DOI 10.1002/bjs.12003↗
  8. Effect of platelet inhibition with perioperative aspirin on survival in patients undergoing curative resection for pancreatic cancer: a propensity score matche… First author DOI 10.1186/s12893-021-01083-9↗
  9. Identification of the Neurokinin-1 Receptor as Targetable Stratification Factor for Drug Repurposing in Pancreatic Cancer. Co-author DOI 10.3390/cancers13112703↗
  10. [Surgery for isolated local recurrence and metachronous oligometastasis in pancreatic cancer]. Co-author DOI 10.1007/s00104-020-01190-y↗
  11. Prolonged time to treatment initiation in advanced pancreatic cancer patients has no major effect on treatment outcome: a retrospective cohort study controlled… Co-author DOI 10.1007/s00432-019-03061-4↗
  12. Improvement of survival after surgical resection of pancreatic cancer independent of adjuvant chemotherapy in the past two decades - A meta-regression. Last author DOI 10.1016/j.ejso.2020.02.016↗
  13. Respect - A multicenter retrospective study on preoperative chemotherapy in locally advanced and borderline resectable pancreatic cancer. Co-author DOI 10.1016/j.pan.2020.06.012↗
  14. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is f… Co-author DOI 10.1016/j.suronc.2020.08.031↗
  15. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  16. Indirect cholinergic activation slows down pancreatic cancer growth and tumor-associated inflammation. Co-author DOI 10.1186/s13046-020-01796-4↗
  17. The Role of Stellate Cells in Pancreatic Ductal Adenocarcinoma: Targeting Perspectives. Last author DOI 10.3389/fonc.2020.621937↗
  18. The role of interleukin-18 in pancreatitis and pancreatic cancer. Last author DOI 10.1016/j.cytogfr.2019.11.001↗
  19. The impact of preoperative biliary stenting in pancreatic cancer: A case-matched study from the German nationwide pancreatic surgery registry (DGAV StuDoQ|Panc… Co-author DOI 10.1016/j.pan.2019.09.007↗
  20. Oligometastatic pulmonary metastasis in pancreatic cancer patients: Safety and outcome of resection. Last author DOI 10.1016/j.suronc.2019.08.010↗
  21. Repurposed Drugs in Pancreatic Ductal Adenocarcinoma: An Update. Co-author DOI 10.1097/ppo.0000000000000372↗
  22. Neoadjuvant Treatment for Borderline Resectable Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1159/000493466↗
  23. Prognostic Impact of Tumor-Infiltrating Lymphocytes and Neutrophils on Survival of Patients with Upfront Resection of Pancreatic Cancer. Last author DOI 10.3390/cancers11010039↗
  24. Therapies Targeting the Tumor Stroma and the VEGF/VEGFR Axis in Pancreatic Ductal Adenocarcinoma: a Systematic Review and Meta-Analysis. Last author DOI 10.1007/s11523-018-0578-x↗
  25. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  26. [Chronic Pancreatitis and Pancreatic Cancer - Tumor Risk and Screening]. First author DOI 10.1055/s-0043-125407↗
  27. Repurposing Established Compounds to Target Pancreatic Cancer Stem Cells (CSCs). First author DOI 10.3390/medsci5020014↗
  28. The novel mitochondria-targeted antioxidant SkQ1 modulates angiogenesis and inflammatory micromilieu in a murine orthotopic model of pancreatic cancer. Co-author DOI 10.1002/ijc.30054↗
  29. [Resectability of pancreatic cancer: New criteria]. Co-author DOI 10.1007/s00117-016-0092-z↗
  30. Anti-tumor properties of the cGMP/protein kinase G inhibitor DT3 in pancreatic adenocarcinoma. Co-author DOI 10.1007/s00210-015-1147-9↗
  31. The neurotrophic factor neurturin contributes toward an aggressive cancer cell phenotype, neuropathic pain and neuronal plasticity in pancreatic cancer. Co-author DOI 10.1093/carcin/bgt312↗

Closest collaborators

The 25 strongest of 112 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Jens Werner · 24 shared papers, 2015–2026 · strength 3.03
  2. Matthias Ilmer · 12 shared papers, 2017–2026 · strength 1.82
  3. Bernhard Willibald Renz · 11 shared papers, 2017–2026 · strength 1.75
  4. Maximilian Weniger · 10 shared papers, 2018–2026 · strength 1.41
  5. Alexandr V. Bazhin · 9 shared papers, 2015–2025 · strength 1.09
  6. Steffen Ormanns · 8 shared papers, 2018–2025 · strength 1.00
  7. Rainer Christoph Miksch · 5 shared papers, 2019–2026 · strength 0.88
  8. Hanno Nieß · 4 shared papers, 2019–2025 · strength 0.54
  9. Stefan Hubert Boeck · 6 shared papers, 2018–2023 · strength 0.51
  10. Julia V. Mayerle · 5 shared papers, 2018–2023 · strength 0.47
  11. Ughur Aghamaliyev · 2 shared papers, 2023–2025 · strength 0.43
  12. Yang Feng Wu · 2 shared papers, 2020–2026 · strength 0.42
  13. Tengis Tschaidse · 2 shared papers, 2025 · strength 0.42
  14. Christoph Benedikt Westphalen · 4 shared papers, 2017–2023 · strength 0.41
  15. Helmut Frieß · 5 shared papers, 2014–2020 · strength 0.40
  16. Georg Beyer · 4 shared papers, 2018–2023 · strength 0.38
  17. Stephan Krüger · 5 shared papers, 2018–2020 · strength 0.38
  18. Michael Haas · 4 shared papers, 2020–2023 · strength 0.38
  19. Guralp Onur Ceyhan · 5 shared papers, 2014–2020 · strength 0.38
  20. Iris Beirith · 2 shared papers, 2021–2025 · strength 0.31
  21. Patrick Maisonneuve · 3 shared papers, 2020 · strength 0.31
  22. Tobias Keck · 2 shared papers, 2019–2025 · strength 0.30
  23. Michael B. Ghadimi · 2 shared papers, 2019–2025 · strength 0.30
  24. Waldemar H. Uhl · 2 shared papers, 2019–2025 · strength 0.30
  25. Volker Heinemann · 3 shared papers, 2020–2023 · strength 0.29

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.